On the 25th, Dt&CRO announced that it had signed a memorandum of understanding (MOU) with Radyus Research, a U.S. clinical consulting organization.

The MOU is expected to add momentum to the company’s full-cycle consulting service that is provided to domestic pharma and biotech companies that apply for Investigational New Drug (IND) or file a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA).

As a GLP-certified organization, Dt&CRO is a full-service CRO capable of conducting non-clinical trials, Phase I-III clinical trials, post-marketing surveillance (PMS), observational studies (OS), as well as pharmacovigilance (PV) s